CA3001314A1 - Multiplexed genome editing of retroviral elements - Google Patents
Multiplexed genome editing of retroviral elements Download PDFInfo
- Publication number
- CA3001314A1 CA3001314A1 CA3001314A CA3001314A CA3001314A1 CA 3001314 A1 CA3001314 A1 CA 3001314A1 CA 3001314 A CA3001314 A CA 3001314A CA 3001314 A CA3001314 A CA 3001314A CA 3001314 A1 CA3001314 A1 CA 3001314A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- nucleic acid
- perv
- rna
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001177 retroviral effect Effects 0.000 title claims description 6
- 238000010362 genome editing Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 63
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 57
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 229920002477 rna polymer Polymers 0.000 claims abstract description 38
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 22
- 230000000295 complement effect Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 173
- 241000881705 Porcine endogenous retrovirus Species 0.000 claims description 118
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 108091033409 CRISPR Proteins 0.000 claims description 27
- 108700004029 pol Genes Proteins 0.000 claims description 26
- 101150088264 pol gene Proteins 0.000 claims description 25
- 108700005077 Viral Genes Proteins 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 210000001082 somatic cell Anatomy 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 210000002980 germ line cell Anatomy 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 58
- 102000053602 DNA Human genes 0.000 description 58
- 108020005004 Guide RNA Proteins 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 230000008685 targeting Effects 0.000 description 21
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 19
- 230000006780 non-homologous end joining Effects 0.000 description 18
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 18
- 241000282898 Sus scrofa Species 0.000 description 17
- 230000035772 mutation Effects 0.000 description 15
- 101710163270 Nuclease Proteins 0.000 description 13
- 210000005260 human cell Anatomy 0.000 description 13
- 230000008439 repair process Effects 0.000 description 13
- 102100034343 Integrase Human genes 0.000 description 12
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 9
- 230000005540 biological transmission Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 229950010131 puromycin Drugs 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000033616 DNA repair Effects 0.000 description 6
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 101710096438 DNA-binding protein Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000003205 genotyping method Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000012070 whole genome sequencing analysis Methods 0.000 description 5
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 101100121731 Sus scrofa GGTA1 gene Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101100215371 Homo sapiens ACTB gene Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000012350 deep sequencing Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 230000005782 double-strand break Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108020004437 Endogenous Retroviruses Proteins 0.000 description 2
- 101000856513 Homo sapiens Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Proteins 0.000 description 2
- 101000618467 Hypocrea jecorina (strain ATCC 56765 / BCRC 32924 / NRRL 11460 / Rut C-30) Endo-1,4-beta-xylanase 2 Proteins 0.000 description 2
- 102100025509 Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Human genes 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 238000011304 droplet digital PCR Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010199 gene set enrichment analysis Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- 244000000023 zoonotic pathogen Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10061—Methods of inactivation or attenuation
- C12N2740/10062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- AIDS & HIV (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Input Circuits Of Receivers And Coupling Of Receivers And Audio Equipment (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239239P | 2015-10-08 | 2015-10-08 | |
| US62/239,239 | 2015-10-08 | ||
| PCT/US2016/055916 WO2017062723A1 (en) | 2015-10-08 | 2016-10-07 | Multiplexed genome editing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3001314A1 true CA3001314A1 (en) | 2017-04-13 |
Family
ID=58488520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3001314A Pending CA3001314A1 (en) | 2015-10-08 | 2016-10-07 | Multiplexed genome editing of retroviral elements |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US10959413B2 (OSRAM) |
| EP (2) | EP3359661B1 (OSRAM) |
| JP (4) | JP7059468B2 (OSRAM) |
| KR (2) | KR102729669B1 (OSRAM) |
| CN (2) | CN108513580A (OSRAM) |
| AU (2) | AU2016335698B2 (OSRAM) |
| CA (1) | CA3001314A1 (OSRAM) |
| CL (1) | CL2018000902A1 (OSRAM) |
| CO (1) | CO2018004763A2 (OSRAM) |
| IL (2) | IL297017A (OSRAM) |
| MX (2) | MX2018004263A (OSRAM) |
| NZ (1) | NZ741778A (OSRAM) |
| SA (2) | SA518391294B1 (OSRAM) |
| WO (1) | WO2017062723A1 (OSRAM) |
| ZA (1) | ZA201802461B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107254551A (zh) * | 2017-06-06 | 2017-10-17 | 北京盖兰德生物科技有限公司 | 一种鉴定和选育PERV‑pol基因缺陷型五指山小型猪近交系新品系的方法 |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| EP4481048A3 (en) * | 2012-12-17 | 2025-02-26 | President and Fellows of Harvard College | Rna-guided human genome engineering |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| IL301900A (en) | 2014-11-21 | 2023-06-01 | Regeneron Pharma | Methods and compositions for targeted genetic modification using paired guide rnas |
| KR102729669B1 (ko) | 2015-10-08 | 2024-11-12 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 다중화 게놈 편집 |
| EP3365356B1 (en) | 2015-10-23 | 2023-06-28 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
| DK3386550T3 (da) | 2015-12-07 | 2021-04-26 | Arc Bio Llc | Fremgangsmåder til fremstilling og anvendelse af guide nukleinsyrer |
| JP7370702B2 (ja) | 2015-12-24 | 2023-10-30 | セレクシス エス．エー． | タンパク質製造用の改善された真核細胞およびそれらの作製方法 |
| JP7324583B2 (ja) | 2016-05-20 | 2023-08-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法 |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| WO2018111640A1 (en) * | 2016-12-14 | 2018-06-21 | Dow Agrosciences Llc | Reconstruction of site specific nuclease binding sites |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| CN116555353A (zh) * | 2017-04-20 | 2023-08-08 | E开创生物技术股份有限公司 | 产生基因修改的动物的方法 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CA3065384A1 (en) * | 2017-06-07 | 2018-12-13 | Arc Bio, Llc | Creation and use of guide nucleic acids |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| KR102103103B1 (ko) | 2018-08-16 | 2020-04-21 | (주)라트바이오 | 인위적 뉴클레아제를 생산하는 형질전환 동물 및 형질전환 배아 |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110358766A (zh) * | 2019-06-10 | 2019-10-22 | 云南农业大学 | 一种基于全基因组CRISPR/Cas9文库筛选异种移植抗原基因的方法 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN111534541A (zh) * | 2020-05-07 | 2020-08-14 | 西南大学 | 一种真核生物CRISPR-Cas9双gRNA载体及构建方法 |
| CN111549060A (zh) * | 2020-05-07 | 2020-08-18 | 西南大学 | 一种真核生物CRISPR/Cas9全基因组编辑细胞文库及构建方法 |
| MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
| CN112280802A (zh) * | 2020-05-21 | 2021-01-29 | 华中农业大学 | 基于piggyBac转座子系统制备稳定表达BE4蛋白的猪肾上皮细胞系的方法 |
| CA3237300A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
| WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
| CN114438083A (zh) * | 2022-01-29 | 2022-05-06 | 五邑大学 | 识别猪PERV基因的sgRNA及其编码DNA和应用 |
| WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
| WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
| WO2024234006A1 (en) | 2023-05-11 | 2024-11-14 | Tome Biosciences, Inc. | Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs) |
| WO2025050069A1 (en) | 2023-09-01 | 2025-03-06 | Tome Biosciences, Inc. | Programmable gene insertion using engineered integration enzymes |
| WO2025224107A1 (en) | 2024-04-22 | 2025-10-30 | Basecamp Research Ltd | Method and compositions for detecting off-target editing |
| WO2025224182A2 (en) | 2024-04-23 | 2025-10-30 | Basecamp Research Ltd | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3099801A (en) | 2000-01-19 | 2001-07-31 | Biotransplant Incorporated | Swine defective for transmission of porcine endogenous retrovirus and uses thereof |
| CN1972593A (zh) * | 2003-11-21 | 2007-05-30 | 雷维维科公司 | 干扰rna在生产转基因动物中的用途 |
| EP1582591A3 (en) | 2004-02-27 | 2005-12-21 | Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut | Sirna and their use for knock down expression of porcine endogenous retrovirus |
| NZ539491A (en) * | 2005-04-15 | 2008-04-30 | Living Cell Products Pty Ltd | Swine population and uses thereof |
| EP2077329A1 (en) * | 2008-01-04 | 2009-07-08 | MWM Biomodels GmbH | Transgenic pig with altered incretin function |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| EP4481048A3 (en) * | 2012-12-17 | 2025-02-26 | President and Fellows of Harvard College | Rna-guided human genome engineering |
| KR102733409B1 (ko) | 2013-06-05 | 2024-11-21 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
| CN106102781A (zh) | 2013-08-29 | 2016-11-09 | 英联邦高等教育系统天普大学 | 用于hiv感染的rna指导的治疗的方法和组合物 |
| CA2932479A1 (en) * | 2013-12-12 | 2015-06-18 | The Rockefeller University | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
| MA41382A (fr) | 2015-03-20 | 2017-11-28 | Univ Temple | Édition génique basée sur le système crispr/endonucléase à induction par tat |
| DE102015207944A1 (de) | 2015-04-29 | 2016-11-03 | Wacker Chemie Ag | Verfahren zur Herstellung organisch modifizierter Aerogele |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CN105154471A (zh) * | 2015-08-11 | 2015-12-16 | 南方医科大学珠江医院 | 低表达或不表达perv的肝细胞的制备方法 |
| KR102729669B1 (ko) | 2015-10-08 | 2024-11-12 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 다중화 게놈 편집 |
| JP7370702B2 (ja) | 2015-12-24 | 2023-10-30 | セレクシス エス．エー． | タンパク質製造用の改善された真核細胞およびそれらの作製方法 |
| CN110546267B (zh) * | 2017-02-01 | 2024-09-13 | 哈佛学院董事及会员团体 | 提高细胞基因编辑效率的方法 |
| CN116555353A (zh) * | 2017-04-20 | 2023-08-08 | E开创生物技术股份有限公司 | 产生基因修改的动物的方法 |
-
2016
- 2016-10-07 KR KR1020187012502A patent/KR102729669B1/ko active Active
- 2016-10-07 KR KR1020247037262A patent/KR102880582B1/ko active Active
- 2016-10-07 WO PCT/US2016/055916 patent/WO2017062723A1/en not_active Ceased
- 2016-10-07 IL IL297017A patent/IL297017A/en unknown
- 2016-10-07 US US15/766,551 patent/US10959413B2/en active Active
- 2016-10-07 EP EP16854392.4A patent/EP3359661B1/en active Active
- 2016-10-07 CA CA3001314A patent/CA3001314A1/en active Pending
- 2016-10-07 EP EP24214109.1A patent/EP4491732A3/en active Pending
- 2016-10-07 CN CN201680071844.2A patent/CN108513580A/zh active Pending
- 2016-10-07 NZ NZ741778A patent/NZ741778A/en unknown
- 2016-10-07 AU AU2016335698A patent/AU2016335698B2/en active Active
- 2016-10-07 JP JP2018518438A patent/JP7059468B2/ja active Active
- 2016-10-07 CN CN202211152246.1A patent/CN116064664A/zh active Pending
- 2016-10-07 MX MX2018004263A patent/MX2018004263A/es unknown
-
2018
- 2018-02-05 US US15/888,581 patent/US10375938B2/en active Active
- 2018-04-06 MX MX2024007924A patent/MX2024007924A/es unknown
- 2018-04-06 CL CL2018000902A patent/CL2018000902A1/es unknown
- 2018-04-07 SA SA518391294A patent/SA518391294B1/ar unknown
- 2018-04-07 SA SA523441205A patent/SA523441205B1/ar unknown
- 2018-04-08 IL IL258536A patent/IL258536A/en unknown
- 2018-04-13 ZA ZA2018/02461A patent/ZA201802461B/en unknown
- 2018-05-03 CO CONC2018/0004763A patent/CO2018004763A2/es unknown
-
2019
- 2019-08-05 US US16/531,351 patent/US11064684B2/en active Active
- 2019-12-10 US US16/708,655 patent/US10925263B2/en active Active
-
2020
- 2020-12-11 US US17/118,684 patent/US12133515B2/en active Active
-
2021
- 2021-03-04 JP JP2021034493A patent/JP7144122B2/ja active Active
- 2021-12-02 JP JP2021196238A patent/JP7420439B2/ja active Active
-
2022
- 2022-05-06 JP JP2022076779A patent/JP7473136B2/ja active Active
-
2023
- 2023-02-28 AU AU2023201178A patent/AU2023201178B2/en active Active
-
2024
- 2024-09-27 US US18/899,268 patent/US20250017181A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107254551A (zh) * | 2017-06-06 | 2017-10-17 | 北京盖兰德生物科技有限公司 | 一种鉴定和选育PERV‑pol基因缺陷型五指山小型猪近交系新品系的方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250017181A1 (en) | Multiplexed Genome Editing | |
| Flynn et al. | CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells | |
| Wang et al. | Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies | |
| Bialk et al. | Regulation of gene editing activity directed by single-stranded oligonucleotides and CRISPR/Cas9 systems | |
| Yang et al. | Optimization of scarless human stem cell genome editing | |
| CN110546267B (zh) | 提高细胞基因编辑效率的方法 | |
| Zhang et al. | Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling | |
| Jacobs et al. | CRISPR/Cas9-mediated genome editing in naïve human embryonic stem cells | |
| CN116716298A (zh) | 一种引导编辑系统和目的基因序列的定点修饰方法 | |
| HK40117714A (en) | Multiplexed genome editing | |
| HK1259655B (en) | Multiplexed genome editing | |
| HK1259655A1 (en) | Multiplexed genome editing | |
| BR112018007177B1 (pt) | Métodos para alterar os genes pol de perv em uma célula, para gerar uma célula porcina substancialmente livre de perv, para inativar a expressão de uma ou mais sequências alvo de ácido nucleico em uma célula e para modular uma ou mais sequências alvo de ácido nucleico em uma célula | |
| US20250293873A1 (en) | Genomic cryptography | |
| Weuring et al. | Efficient and accurate prime editing strategy to correct genetic alterations in hiPSC using single EF-1alpha driven all-in-one plasmids | |
| Volf | Base Editing–Enabled Technologies and Multiplex Genome Editing | |
| Park et al. | MSH2 and MSH6 as size dependent cellular determinants for prime editing in human embryonic stem cells | |
| Yang | Development of Human Genome Editing Tools for the Study of Genetic Variations and Gene Therapies | |
| Wang et al. | JOIN AAAS | |
| NZ754902A (en) | Genome engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210730 |
|
| EEER | Examination request |
Effective date: 20210730 |
|
| EEER | Examination request |
Effective date: 20210730 |
|
| EEER | Examination request |
Effective date: 20210730 |
|
| EEER | Examination request |
Effective date: 20210730 |
|
| EEER | Examination request |
Effective date: 20210730 |
|
| EEER | Examination request |
Effective date: 20210730 |
|
| EEER | Examination request |
Effective date: 20210730 |